Acetaminophen Dextromethorphan Hydrobromide Tripro
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Acetaminophen Dextromethorphan Hydrobromide Tripro
- ACETAMINOPHEN / DEXTROMETHORPHAN / TRIPROLIDINE: Cold Symptom Combination — No Repurposing Prediction Available
ACETAMINOPHEN / DEXTROMETHORPHAN / TRIPROLIDINE: Cold Symptom Combination — No Repurposing Prediction Available
One-Sentence Summary
This is a three-component OTC cold and flu combination product containing a pain reliever/antipyretic (acetaminophen), a cough suppressant (dextromethorphan hydrobromide), and a first-generation antihistamine (triprolidine), commonly used to relieve cold symptoms such as fever, cough, and runny nose.
The TxGNN model returned no predicted new indications for this combination query, and the drug has no marketing authorization in Taiwan (US regulatory data not applicable). At this stage, there is insufficient data to perform a drug repurposing evaluation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Cold & flu symptom relief (fever, cough, rhinorrhea) — based on known pharmacology of the three components |
| Predicted New Indication | None (TxGNN returned no predictions) |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction not available; no supporting studies identified |
| US Market Status | Not marketed in Taiwan; US status not queried |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
No TxGNN prediction was returned for this drug combination. This is likely because the query was submitted as a multi-component string (ACETAMINOPHEN; DEXTROMETHORPHAN HYDROBROMIDE; TRIPROLIDINE) rather than as individual DrugBank-mapped entities. The TxGNN knowledge graph operates on single drug nodes identified by DrugBank ID; combination strings without a corresponding DrugBank ID cannot be matched to the graph.
Each component has well-characterised pharmacology individually:
- Acetaminophen inhibits prostaglandin synthesis centrally (COX-3), producing analgesia and antipyresis.
- Dextromethorphan HBr is a non-opioid NMDA receptor antagonist and sigma-1 receptor agonist that suppresses the cough reflex.
- Triprolidine is a first-generation H1 antihistamine that reduces rhinorrhea and sneezing.
Running three separate TxGNN queries (one per component) and cross-referencing the results would be the appropriate next step to identify any repurposing signals.
US Market Information
No marketing authorizations were found for this combination in Taiwan. No US NDA data was queried in this Evidence Pack.
Safety Considerations
No safety data (warnings, contraindications, or drug interactions) is currently available for this combination entry. Before any further evaluation, the following should be retrieved:
- Package insert warnings and contraindications from the original manufacturers of each component.
- Drug–drug interaction profile for the three-way combination (particularly dextromethorphan’s known interactions with MAOIs and serotonergic agents, and triprolidine’s CNS depressant interactions).
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN pipeline returned no predictions because this entry was submitted as a multi-component combination string without a DrugBank ID, which the knowledge graph cannot process. There is no Taiwan market presence to anchor a regulatory pathway, and safety data has not been retrieved.
To proceed, the following is needed:
- Decompose the query: Run TxGNN predictions separately for acetaminophen (DB00316), dextromethorphan (DB00514), and triprolidine (DB00786) using their individual DrugBank IDs.
- Retrieve MOA data: Query DrugBank API for each component’s mechanism of action to support mechanistic plausibility analysis.
- Retrieve safety data: Download package inserts from TFDA or FDA for each active ingredient to populate warnings and contraindications.
- Confirm regulatory scope: Clarify whether the repurposing target is the fixed-dose combination or one of the individual components, as this determines the regulatory and IP strategy.
- Re-run the Evidence Pack: Once DrugBank IDs are resolved and individual predictions are available, re-generate this report.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.